In addition to announcing its rebranding to Hilo, Aktiia, a blood pressure intelligence platform, has completed an oversubscribed $42 million Series B funding round, bringing the company’s total funding to date to $100 million. Co-led by Earlybird Health and Wellington Partners, the proceeds from round will accelerate expansion into new markets.
With more than 120,000 devices sold, Hilo has already established itself as a stand-out in the health tech space. Based in Neuchâtel, the company has developed a foundation Machine Learning model specifically designed for blood pressure. The model has been trained on tens of billions of optical signals from real-world users and further refined with hundreds of millions of calibration points, strengthening its position as the leader in the emerging cuffless blood pressure monitoring (CBPM) category.
The company has been experiencing significant momentum, with several major milestones achieved, including securing CE marking for its innovative mobile phone camera blood pressure monitoring technology, securing regulatory approvals in Canada, Australia and Saudi Arabia, achieving 76% compounded annual revenue growth, and completing a pivotal clinical trial ahead of its U.S. FDA application submission.
The $42 million Series B capital will fuel continued product innovation and allow the company to build out of its blood pressure intelligence platform to support enterprise use cases. The capital strengthens Hilo’s position to enter markets and significantly expand its footprint in the German market. New marketing channels will be launched to drive brand awareness, educating the market on the clinically backed health benefits of Hilo, and accelerating product innovation to improve the lives of German customers.
The round was co-led by Earlybird Health and Wellington Partners with new investors Kfund and naturalX Health Ventures, and participation from existing investors redalpine, Khosla Ventures, Molten Ventures, Translink Capital and Verve Ventures. The investment brought the total financing to date above $100 million.
From Aktiia to Hilo
Rebranding to Hilo reflects on the company’s global ambition to make cuffless, clinically validated blood pressure monitoring universally accessible and effortless. The transition to Hilo marks an important milestone in the company’s journey, aligning with its vision of healthier blood pressure for all, while continuing to deliver the trusted technology and reports that have been central to its platform.
Raghav “Rags” Gupta, CEO of Hilo, commented: “This funding round is a testament to the confidence our investors have in Hilo’s groundbreaking technology and our mission to manage the world’s blood pressure via more frequent, convenient and accurate measurements. With billions worldwide suffering from hypertension, only 20% of whom are in control of their blood pressure, the need for innovative, accessible blood pressure monitoring solutions has never been greater. Our rebranding to Hilo represents more than just a name change, it’s a commitment to empowering users around the world with smarter tools to optimise their health. We are grateful to early Aktiia customers for their support and to our investors, new and existing, for their faith.”
Leave a Reply